Brown & Brown remains a Buy following a recent pullback in share value that offers a compelling entry point for long‐term investors. The company has delivered positive earnings per share in each of the last 22 fiscal years and has grown book value per share at a compounded annual rate of 11% over the past decade. Analysts note that the current valuation implies a discount to the firm’s historical trading multiples and its peer group, making it well positioned for upside when broader market sentiment improves.

Organic revenue growth decelerated in the latest quarter, largely attributable to the absence of several nonrecurring commission events that boosted comparisons a year ago, along with declining rates in certain catastrophe‐exposed lines of business. Management has characterized these factors as temporary, pointing to stabilization in pricing trends in January and February. Excluding these items, core organic growth is estimated at roughly 4%, in line with pre–pandemic norms.

The firm’s disciplined acquisition strategy continues to underpin long-term value creation. Brown & Brown ended the year with over 50 potential targets in due diligence, representing an aggregate annualized revenue run rate in excess of $1.2 billion. Scale benefits and integration synergies are expected to support free cash flow per share of $2.08 in 2025, up approximately 10% from 2024 levels. At that pace, the company’s return on invested capital should remain above 12%, well above its weighted average cost of capital.

In Q4, Brown & Brown reported higher commission and fee income, driven by strong renewal retention in middle-market and public entity segments. Investment income rose 15% year-over-year as the fixed-income portfolio benefitted from higher reinvestment rates. Adjusted EBITDAC increased by 8%, more than offsetting the decline in organic revenues. Management reaffirmed full‐year guidance for mid‐single-digit earnings per share growth and emphasized continued cost discipline to support margin expansion.